Hyaluronic acid-green tea catechin conjugates as a potential therapeutic agent for rheumatoid arthritis
Fibroblast-like synoviocytes are a key effector cell type involved in the pathogenesis of rheumatoid arthritis. The major green tea catechin, epigallocatechin-3- O -gallate (EGCG), has attracted significant interest for rheumatoid arthritis therapy because of its ability to suppress the proliferatio...
Saved in:
Published in | RSC advances Vol. 11; no. 24; pp. 14285 - 14294 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Royal Society of Chemistry
19.04.2021
The Royal Society of Chemistry |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Fibroblast-like synoviocytes are a key effector cell type involved in the pathogenesis of rheumatoid arthritis. The major green tea catechin, epigallocatechin-3-
O
-gallate (EGCG), has attracted significant interest for rheumatoid arthritis therapy because of its ability to suppress the proliferation and interleukin-6 secretion of synoviocytes. However, therapeutic efficacy of EGCG has been limited by a lack of target cell specificity. Herein we report hyaluronic acid-EGCG (HA-EGCG) conjugates as an anti-arthritic agent that is capable of targeting fibroblast-like synoviocytes
via
HA-CD44 interactions. These conjugates exhibited superior anti-proliferative and anti-inflammatory activities compared with EGCG under simulated physiological conditions. Near-infrared fluorescence imaging revealed preferential accumulation of the conjugates at inflamed joints in a collagen-induced arthritis rat model, and their anti-arthritic efficacy was investigated by measuring a change in the edema and histopathological scores. Our findings suggest the potential of HA-EGCG conjugates as an anti-arthritic agent for the treatment of rheumatoid arthritis.
Macromolecular HA-EGCG conjugates undergo targeted internalization by CD44-overexpressing fibroblast-like synoviocytes and subsequently cause H
2
O
2
-induced cell death and inhibition of IL-6 secretion, thereby suppressing the progression of arthritis. |
---|---|
Bibliography: | 10.1039/d1ra01491a Electronic supplementary information (ESI) available. See DOI ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 2046-2069 2046-2069 |
DOI: | 10.1039/d1ra01491a |